A citation-based method for searching scientific literature

Roger S McIntyre, Ioana Florea, Brigitte Tonnoir, Henrik Loft, Raymond W Lam, Michael Cronquist Christensen. J Clin Psychiatry 2017
Times Cited: 45







List of co-cited articles
334 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


A Randomized, Placebo-Controlled, Active-Reference, Double-Blind, Flexible-Dose Study of the Efficacy of Vortioxetine on Cognitive Function in Major Depressive Disorder.
Atul R Mahableshwarkar, John Zajecka, William Jacobson, Yinzhong Chen, Richard S E Keefe. Neuropsychopharmacology 2015
152
51

A randomized, double-blind, placebo-controlled study of vortioxetine on cognitive function in depressed adults.
Roger S McIntyre, Søren Lophaven, Christina K Olsen. Int J Neuropsychopharmacol 2014
209
44




Cognitive deficits and functional outcomes in major depressive disorder: determinants, substrates, and treatment interventions.
Roger S McIntyre, Danielle S Cha, Joanna K Soczynska, Hanna O Woldeyohannes, Laura Ashley Gallaugher, Paul Kudlow, Mohammad Alsuwaidan, Anusha Baskaran. Depress Anxiety 2013
347
28

The impact of cognitive impairment on perceived workforce performance: results from the International Mood Disorders Collaborative Project.
Roger S McIntyre, Joanna Z Soczynska, Hanna O Woldeyohannes, Mohammad T Alsuwaidan, Danielle S Cha, André F Carvalho, Jeanette M Jerrell, Roman M Dale, Laura A Gallaugher, David J Muzina,[...]. Compr Psychiatry 2015
84
26

Discovery of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): a novel multimodal compound for the treatment of major depressive disorder.
Benny Bang-Andersen, Thomas Ruhland, Morten Jørgensen, Garrick Smith, Kristen Frederiksen, Klaus Gjervig Jensen, Huailing Zhong, Søren Møller Nielsen, Sandra Hogg, Arne Mørk,[...]. J Med Chem 2011
253
24


The safety and tolerability of vortioxetine: Analysis of data from randomized placebo-controlled trials and open-label extension studies.
David S Baldwin, Lambros Chrones, Ioana Florea, Rebecca Nielsen, George G Nomikos, William Palo, Elin Reines. J Psychopharmacol 2016
57
22

A meta-analysis of randomized, placebo-controlled trials of vortioxetine for the treatment of major depressive disorder in adults.
Michael E Thase, Atul R Mahableshwarkar, Marianne Dragheim, Henrik Loft, Eduard Vieta. Eur Neuropsychopharmacol 2016
59
20

Increase in work productivity of depressed individuals with improvement in depressive symptom severity.
Madhukar H Trivedi, David W Morris, Stephen R Wisniewski, Ira Lesser, Andrew A Nierenberg, Ella Daly, Benji T Kurian, Bradley N Gaynes, G K Balasubramani, A John Rush. Am J Psychiatry 2013
74
20

Pharmacological effects of Lu AA21004: a novel multimodal compound for the treatment of major depressive disorder.
A Mørk, A Pehrson, L T Brennum, S Møller Nielsen, H Zhong, A B Lassen, S Miller, L Westrich, N J Boyle, C Sánchez,[...]. J Pharmacol Exp Ther 2012
188
17



Cognitive impairment in the remitted state of unipolar depressive disorder: a systematic review.
Bo Jacob Hasselbalch, Ulla Knorr, Lars Vedel Kessing. J Affect Disord 2011
240
17


Vortioxetine (Lu AA21004), a novel multimodal antidepressant, enhances memory in rats.
Arne Mørk, Liliana P Montezinho, Silke Miller, Crista Trippodi-Murphy, Niels Plath, Yan Li, Maria Gulinello, Connie Sanchez. Pharmacol Biochem Behav 2013
98
15

Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report.
A John Rush, Madhukar H Trivedi, Stephen R Wisniewski, Andrew A Nierenberg, Jonathan W Stewart, Diane Warden, George Niederehe, Michael E Thase, Philip W Lavori, Barry D Lebowitz,[...]. Am J Psychiatry 2006
15

Cognitive impairment in depression: a systematic review and meta-analysis.
P L Rock, J P Roiser, W J Riedel, A D Blackwell. Psychol Med 2014
699
15


Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis.
Andrea Cipriani, Toshi A Furukawa, Georgia Salanti, Anna Chaimani, Lauren Z Atkinson, Yusuke Ogawa, Stefan Leucht, Henricus G Ruhe, Erick H Turner, Julian P T Higgins,[...]. Lancet 2018
824
15

Vortioxetine, but not escitalopram or duloxetine, reverses memory impairment induced by central 5-HT depletion in rats: evidence for direct 5-HT receptor modulation.
Jesper Bornø Jensen, Kristian Gaarn du Jardin, Dekun Song, David Budac, Gennady Smagin, Connie Sanchez, Alan Lars Pehrson. Eur Neuropsychopharmacol 2014
68
13


Mediators of the association between depression and role functioning.
M A Buist-Bouwman, J Ormel, R de Graaf, P de Jonge, E van Sonderen, J Alonso, R Bruffaerts, W A M Vollebergh. Acta Psychiatr Scand 2008
84
13

A randomized, double-blind, placebo-controlled 8-week trial of the efficacy and tolerability of multiple doses of Lu AA21004 in adults with major depressive disorder.
Neven Henigsberg, Atul R Mahableshwarkar, Paula Jacobsen, Yinzhong Chen, Michael E Thase. J Clin Psychiatry 2012
104
13

A randomized, double-blind, duloxetine-referenced study comparing efficacy and tolerability of 2 fixed doses of vortioxetine in the acute treatment of adults with MDD.
Atul R Mahableshwarkar, Paula L Jacobsen, Yinzhong Chen, Michael Serenko, Madhukar H Trivedi. Psychopharmacology (Berl) 2015
56
13

Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section 3. Pharmacological Treatments.
Sidney H Kennedy, Raymond W Lam, Roger S McIntyre, S Valérie Tourjman, Venkat Bhat, Pierre Blier, Mehrul Hasnain, Fabrice Jollant, Anthony J Levitt, Glenda M MacQueen,[...]. Can J Psychiatry 2016
363
13


The prevalence, measurement, and treatment of the cognitive dimension/domain in major depressive disorder.
Roger S McIntyre, Holly X Xiao, Kahlood Syeda, Maj Vinberg, Andre F Carvalho, Rodrigo B Mansur, Nadia Maruschak, Danielle S Cha. CNS Drugs 2015
57
11


A double-blind, randomized, placebo-controlled, active reference study of Lu AA21004 in patients with major depressive disorder.
Enric Alvarez, Victor Perez, Marianne Dragheim, Henrik Loft, Francesc Artigas. Int J Neuropsychopharmacol 2012
149
11

A randomized, double-blind, placebo-controlled study of the efficacy and safety of vortioxetine 10 mg and 20 mg in adults with major depressive disorder.
Paula L Jacobsen, Atul R Mahableshwarkar, Michael Serenko, Serena Chan, Madhukar H Trivedi. J Clin Psychiatry 2015
64
11

Which Cognitive Domains are Improved by Treatment with Vortioxetine?
John E Harrison, Søren Lophaven, Christina K Olsen. Int J Neuropsychopharmacol 2016
28
17


The effect of depression treatment on work productivity.
Arne Beck, Lauren A Crain, Leif I Solberg, Jürgen Unützer, Michael V Maciosek, Robin R Whitebird, Rebecca C Rossom. Am J Manag Care 2014
23
21

Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice.
Madhukar H Trivedi, A John Rush, Stephen R Wisniewski, Andrew A Nierenberg, Diane Warden, Louise Ritz, Grayson Norquist, Robert H Howland, Barry Lebowitz, Patrick J McGrath,[...]. Am J Psychiatry 2006
11

The measurement of disability.
D V Sheehan, K Harnett-Sheehan, B A Raj. Int Clin Psychopharmacol 1996
927
11

The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R).
Ronald C Kessler, Patricia Berglund, Olga Demler, Robert Jin, Doreen Koretz, Kathleen R Merikangas, A John Rush, Ellen E Walters, Philip S Wang. JAMA 2003
11

The economic burden of adults with major depressive disorder in the United States (2005 and 2010).
Paul E Greenberg, Andree-Anne Fournier, Tammy Sisitsky, Crystal T Pike, Ronald C Kessler. J Clin Psychiatry 2015
751
11

Neurocognitive deficits and disability in major depressive disorder.
Judith Jaeger, Stefanie Berns, Sarah Uzelac, Sara Davis-Conway. Psychiatry Res 2006
307
11

A meta-analysis of cognitive deficits in first-episode Major Depressive Disorder.
Rico S C Lee, Daniel F Hermens, Melanie A Porter, M Antoinette Redoblado-Hodge. J Affect Disord 2012
419
11

Cognitive dysfunction in major depressive disorder: a state-of-the-art clinical review.
Beatrice Bortolato, Andre F Carvalho, Roger S McIntyre. CNS Neurol Disord Drug Targets 2014
108
11

The multimodal antidepressant vortioxetine may facilitate pyramidal cell firing by inhibition of 5-HT3 receptor expressing interneurons: An in vitro study in rat hippocampus slices.
Elena Dale, Morten Grunnet, Alan L Pehrson, Kristen Frederiksen, Peter H Larsen, Jacob Nielsen, Tine B Stensbøl, Bjarke Ebert, Haolan Yin, Dunguo Lu,[...]. Brain Res 2018
11
45

Vortioxetine reduces BOLD signal during performance of the N-back working memory task: a randomised neuroimaging trial in remitted depressed patients and healthy controls.
J Smith, M Browning, S Conen, R Smallman, J Buchbjerg, K G Larsen, C K Olsen, S R Christensen, G R Dawson, J F Deakin,[...]. Mol Psychiatry 2018
27
18







Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.